What Nurix Therapeutics, Inc. told the SEC could break it.

Nurix relies on third parties located in China for some of its contract manufacturing and expects to continue doing so. It states that for any activities conducted in China it is exposed to the possibility of product supply disruption and increased costs in the event of changes in Chinese policies (and, implicitly, U.S. policy toward Chinese biomanufacturing, e.g. BIOSECURE-style restrictions). For a clinical-stage company dependent on CMOs, a China-sourced manufacturing disruption or a forced decoupling from Chinese CMOs could delay its programs. A specific China-manufacturing geographic/policy dependence relevant to the supply-shock thesis.

“we rely on third parties located in China for some of our contract manufacturing, and we expect to continue to use such third-party manufacturers for such purposes.”

Nurix owns no manufacturing facilities and relies entirely on third-party contract manufacturing organizations (CMOs) for both drug substance and finished drug product, with single-source manufacturers and suppliers for the supply of its drug candidates. Where one CMO is the sole source of a given drug substance or finished product, an interruption, quality failure or capacity shortfall would delay, prevent or impair its development and any future commercialization. As a clinical-stage company this primarily threatens trial supply today, but it is a structural sole-source dependence across its pipeline. A real single-source manufacturing exposure.

“The Company relies on single source manufacturers and suppliers for the supply of its drug candidates.”